Skip to main content
Premium Trial:

Request an Annual Quote

MNM Bioscience Wins $800K Eurostars Grant to Stratify Ovarian Cancer Patients

NEW YORK – Bioinformatics startup MNM Bioscience said Monday that it has received an $800,000 Eurostars grant to develop a software tool for the stratification of patients with ovarian cancer.

The Boston-based firm will work with partner Macrogen Europe to develop a product called PARPiNDx, which will apply artificial intelligence to whole-genome sequencing data to find patients likely to respond to PARP inhibitors, as well as those with intrinsic resistance to the drug family.

MNM Bioscience said that it entered into a consortium agreement with Macrogen Europe on March 24. Neither company provided additional details about their consortium.